In this AJMC® roundtable discussion, oncology health care decision-making experts consider factors that affect the use of cancer immunotherapies (CITs) and discuss approaches for actualizing policies and procedures within community oncology teams.
Evaluating the Management of Cancer Immunotherapy (CIT): Roundtable Discussion
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5